TLR-4: An Inflammatory Link to Prostate Cancer
Abstract
Keywords
Full Text:
PDFReferences
Weinberg RA, Hanahan D. The Hallmarks of Cancer. Cell. 2000; 100: 57p.
Coussens LM, Werb Z. Inflammation and Cancer. Nature (Lond). 2002; 420: 860–867p.
Mazro AM, Sutcliffe S, Platz EA, et al. Inflammation in Prostate Carcinogenesis. Nature. 2007; 7: 256–269p.
Mantovani A, Garlanda C. Inflammation and Multiplemyeloma: The Toll Connection. Leukemia. 2006; 20: 937–938p.
Kim HM, et al. Crystal Structure of the TLR4-MD-2 Complex with Bound Endotoxin Antagonist Eritoran. Cell. 2007; 130: 906–917p.
Li L. Regulation of Innate Immunity Signaling and its Connection with Human Diseases. Curr. Drugs Targets Inflamm Allergy. 2004; 3(1): 81–6p.
Chowdhury P, Sacks SH, Sheerin NS. Toll-Like Receptors TLR2 and TLR4 Initiate the Innate Immune Response of the Renal Tubular Epithelium to Bacterial Products. Clin. Exp. Immunol. 2006; 145: 346–356p.
Weindi G, Naglik JR, Kaesler S, et al. Human Epithelial Cells Establish Direct Antifungal Defense through TLR4-Mediated Signaling. J. Clin. Invest. 2007; 117: 3664–3672p.
Huang B, Zhao J, Li H, et al. Toll-Like Receptors on Tumor Cells Facilitate Evasion of Immune Surveillance. Cancer Res. 2005; 65: 5009–5014p.
Faure E, Thomas S, Xu H, et al. Bacterial LPS and IFN- Induce TLR-4 Expression in Human Endothelial Cells. J. Immunol. 2001; 166: 2018–2024p.
Kopp EB, Medzhitov R. The Toll Receptor Family and Control of Innate Immunity. Curr. Opin. Immunol. 1999; 11: 13–18p.
Child NJ, Yang IA, Pulletz MC, et al. Polymorphisms in Toll-Like Receptor 4 and the Systemic Inflammatory Response Syndrome. Biochem Soc Trans. 2003; 31: 652–653p.
Lorenz E, Mira JP, Cornish KL, et al. A Novel Polymorphism in the Toll-Like Receptor 2 Gene and its Potential Association with Staphylococcal Infection. Infect Immun. 2000; 68: 6398–401p.
Kiechl S, Lorenz E, Reindl M, et al. Toll-Like Receptor 4 Polymorphisms and Atherogenesis. N Engl J Med. 2002; 347: 185–92p.
Zheng SL, Augustsson-Balter K, Chang B, et al. Sequence Variants of TLR-4 are Associated with Prostate Cancer Risk: Results from the Cancer Prostate in Sweden Study. Can. Res. 2004; 4: 2918–2922p.
Chen YC, Giovannucci E, Lazarus R, et al. Sequence Variants of Toll-Like
Receptor 4 and Susceptibility to Prostate Cancer. Cancer Res. 2005; 65: 11771–11778p.
Karin M, Greten FR. NF-κB: Linking Inflammation and Immunity to Cancer Development and Progression. Nat. Rev. Immunol. 2005; 5: 749–759p.
Karin M, Lawrence T, Nizet V. Innate Immunity Gone Awry: Linking Microbial Infections to Chronic Inflammation and Cancer. Cell. 2006; 124: 823–835p.
Conti B, Tabarean I, AndréI C, et al. Cytokines and Fever. Front Biosci. 2004; 9: 1433–1449p.
Cheng J, Cao W, Steinberg RH, et al. PGE2 Induces VEGF and Basic Fibroblast Growth Factor mRNA Expression in Cultured Rat Muller Cells. Investig. Opthalmol. Vis. Sci. 1998; 39: 581–591p.
Gupta S, Afaq F, Mukhtar H. Involvement of Nuclear Factor-Kappa B, Bax and Bcl-2 in Induction of Cell Cycle Arrest and Apoptosis by Apigenin in Human Prostate Carcinoma Cells. Oncogene. 2002; 21: 3727–38p.
Karin M, Cao Y, Greten FR. NF-κB in Cancer: From Innocent Bystander to Major Culprit. Nat. Rev. Cancer. 2002; 2: 301–310p.
Smith MF Jr, Mitchell A, Li G, et al. Toll-Like Receptor (TLR) 2 and TLR5, but not TLR4, are required for Helicobacter Pylori-Induced NF-Kappa B Activation and Chemokine Expression by Epithelial Cells. J Biol Chem. 2003; 278: 32552–60p.
Luo JL, Kamata H, Karin M. IKK/NF-κB Signaling: Balancing Life and Death-A New Approach to Cancer Therapy. J. Clin. Invest. 2005; 2625–2632p.
Parkin DM, Whelan SL, Ferlay J, et al. Cancer Incidence in Five Continents. Vol VII. Lyon: IARC Sci Publ. 1997.
Heyen JR, Ye S, Finck B, et al. Johnson RW. Interleukin (IL)-10 Inhibits IL-6 Production in Microglia by Preventing Activation of NF-Kappa B. Brain Res Mol Brain Res. 2000; 77: 138–147p.
Dennis LK, Dawson DV. Meta-Analysis of Measures of Sexual Activity and Prostate Cancer. Epidemiology. 2002; 13: 72–75p.
Dennis LK, Lynch CF, Torner JC. Epidemiologic Association between Prostatitis and Prostate Cancer. Urology. 2002; 60: 78–83p.
Priyadarshini A, Chakraborti Mandal AK, Singh SK. Asp299Gly and Thr399Ile Polymorphism of TLR-4 Gene in Patients with Prostate Cancer from North India. Indian J of Urology. 2013; 29(1): 37–41p.
Akira S, Hemmi H. Recognition of Pathogen Associated Molecular Patterns by TLR Family. Immunol. Lett. 2003; 85: 85–95p.
Check W. Innate Immunity Depends on TLR’s. ASM News. 2004; 70: 317–322p.
Medzhitov R, Janeway C Jr. Innate Immunity. N. Engl. J. Med. 2000; 343: 338–44p.
Yarovinsky F, et al. TLR11 Activation of Dendritic Cells by a Protozoan Profilin-Like Protein. Science. 2005; 308: 1626–1629p.
Takeda K, Kaisho T, Akira S. Toll-Like Receptors. Annu Rev Immunol. 2003; 21: 335–376p.
Lemaitre B, Nicolas E, Michaut L, et al. The Dorsoventral Regulatory Gene Cassette Spatzle/Toll/Cactus Controls the Potent Antifungal Response in Drosophila Adults. Cell. 1996; 86: 973–83p.
Hoffmann JA. The Immune Response of Drosophila. Nature. 2003; 426: 33–38p.
Medzhitov R, et al. A Human Homologue of the Drosophila Toll Protein Signals Activation of Adaptive Immunity. Nature. 1997; 388: 394–402p.
Schumann RR, et al. Structure and Function of Lipopolysaccharide Binding Protein. Science. 1990; 249: 1429–31p.
Beutler B, Milsark IW, Cerami A, et al. Passive Immunization Against Cachectin/Tumor Necrosis Factor (TNF) Protects Mice from the Lethal Effect of Endotoxin. Science. 1985; 229: 869–871p.
Tracey KJ, Beutler B, Lowry SF, et al. Shock and Tissue Injury Induced by Recombinant Human Cachectin. Science. 1986; 234: 470–474p.
Arbour NC, Lorenz E, Schutte BC, et al. TLR4 Mutations are Associated with Endotoxin Hyporesponsiveness in Humans. Nat Genet. 2000; 25: 187–191p.
Lorenz E, Hallman M, Marttila R, et al. Association between the Asp299Gly Polymorphisms in the Toll-Like Receptor 4 and Premature Births in the Finnish Population. Pediatr Res. 2002; 52: 373–76p.
Ameziane N, Beillat T, Verpillat P, et al. Association of the Toll-Like Receptor 4 Gene Asp299Gly Polymorphism with Acute Coronary Events. Arterioscler Thromb Vasc Biol. 2003; 23: 61–64p.
Hawn TR, Verbon A, Janer M, et al. Toll-Like Receptor 4 Polymorphisms are Associated with Resistance to Legionnaires’ Disease. Proc Natl Acad Sci USA. 2005; 102: 2487–2489p.
Mockenhaupt FP, Cramer JP, Hamann L, et al. Toll-Like Receptor (TLR) Polymorphisms in African Children: Common TLR-4 Variants Predispose to Severe Malaria. Proc Natl Acad Sci USA. 2006; 103: 177–182p.
Sun J, Wiklund F, Zheng SL, et al. Sequence Variants in Toll-Like Receptor Gene Cluster (TLR6-TLR1-TLR10) and Prostate Cancer Risk. J Natl Cancer Inst. 2005; 97: 525–532p.
Iwasaki A, Medzhitov R. Toll Like Receptor Control of the Adaptive Immune Responses. Nat Immmunol. Oct 2004; 5(10): 987–95p.
Zarember KA, Godowski PJ. Tissue Expression of Human Toll-Like Receptors and Differential Regulation of Toll-Like Receptor mRNAs in Leukocytes in Response to Microbes, Their Products, and Cytokines. J. Immunol. 2002; 168: 554–561p.
Takeda K, Akira S. Toll-Like Receptors in Innate Immunity. Int. Immunol. 2005; 17(1): 1–14p.
Kelly MG, Alvero AB, Chen R, et al. TLR-4 Signaling Promotes Tumor Growth and Paclitaxel Chemoresistance in Ovarian Cancer. Cancer Res. 2006; 66: 3859–3868p.
He W, Liu Q, Wang L, et al. TLR4 Signaling Promotes Immune Escape of Human Lung Cancer Cells by Inducing Immunosuppressive Cytokines and Apoptosis Resistance. Mol Immunol. 2007; 44: 2850–2859p.
Chen R, Alvero AB, Silasi DA, et al. Molecular Typing of Epithelial Ovarian Cancer: Implications on Chemoresponse and Tumor Progression. J Clin Invest. 2007.
Baniyash M. Chronic Inflammation, Immunosuppression and Cancer: New Insights and Outlook. Semin. Cancer Biol. 2006; 16: 80–88p.
Bohnhorst J, Rasmussen T, Moen S, et al. Toll-Like Receptors Mediate Proliferation and Survival of Multiple Myeloma Cells. Leukemia. 2006; 20: 1138–1144p.
Du M, Roy KM, Zhong L. et al. VEGF Gene Expression is Regulated Post-Transcriptionally in Macrophages. FEBS J. 2006; 273: 732–745p.
Akira S, Takeda K, Kaisho T. Toll-Like Receptors: Critical Proteins Linking Innate and Acquired Immunity. Nat Immunol. 2001; 2: 675–680p.
Akira S, Takeda K. Toll-Like Receptor Signalling. Nat Rev Immunol. 2004; 4: 499–511p.
Tarta Kovsky B, Kovacs EJ, Takacs L, et al. T Cell Clone Producing IL-1 Activity after Stimulation by Antigen Presenting B-Cell. J. Immunol. 1986; 131: 221–228p.
Fan Fan SO, Liu W, et al. Interleukin 1 Regulates Angiopoietin-1 Expression in Human Endothelial Cells. Cancer Res. 2004; 3186–3190p.
Voronov E, Shouval DS, Krelin, et al. IL-1 is required for Tumor Invasiveness and Angiogenesis. Proc. Natl. Acad. Sci. USA. 2003; 100: 2645–2650p.
Song J, Kim D, Kim C, et al. The Association between Toll-Like Receptor 4 (TLR4) Polymorphisms and the Risk of Prostate Cancer in Korean Men. Cancer Genet Cytogenet. 2003; 190: 88–92p.
Herschman HR. Primary Response Genes Induced by Growth Factors and Tumor Promoters. Ann. Rev. Biochem. 1991; 60: 281–287p.
Liu XH, Kirschenbaum A. Inhibition of COX-2 Suppresses Angiogenesis and the Growth of Prostate Cancer in vivo. J. Urology. 2000; 164: 820–825p.
Tsujii M, Kawano S, Tsujii S, et al. Cyclo-Oxigenase Regulates Angiogenesis Induced by Colon Cancer Cells. Cell. 1998; 93: 405–409p.
Schmedtji JF Jr, Liu YS, DuBois RN, et al. Hypoxia Induces COX-2 via the NF-B p65 Transcription Factor in Human Vascular Endothelial Cells. J. Biol. Chem. 1997; 272: 601–605p.
Chung IB, Yelian FD, Zaher FM. Expression and Regulation of VEGF in the 1’st Trimester Trophoblast Cell Line. Placenta. 2000; 21: 320–324p.
DOI: https://doi.org/10.37628/ijmb.v1i1.22
Refbacks
- There are currently no refbacks.